Plain-language summary

This Phase 3 trial is comparing TR115 and Investigator's Choice against other options for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 18 Years or older
• Lymphoma came back or did not respond to prior treatment
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

TR115 (DRUG): TR115 will be administered orally twice daily until documented disease progression, unacceptable toxicity, withdrawal of consent, death, or study discontinuation. | Investigator's Choice (DRUG): Investigator's choice treatment with chidamide, golidocitinib, mitoxantrone hydrochloride liposome, or gemcitabine hydrochloride administered according to the respective approved prescribing information.

Drugs / treatments

TR115, Investigator's Choice

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details